Stemtech Net Income
| STEK Stock | USD 0.0004 0.0001 33.33% |
As of the 17th of February 2026, Stemtech has the Variance of 195.25, risk adjusted performance of (0.12), and Coefficient Of Variation of (631.12). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stemtech, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Stemtech, which can be compared to its competition.
Analyzing historical trends in various income statement and balance sheet accounts from Stemtech's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Stemtech's valuation are summarized below:Stemtech does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Stemtech |
Stemtech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Stemtech's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Stemtech.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Stemtech on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Stemtech or generate 0.0% return on investment in Stemtech over 90 days. Stemtech is related to or competes with Curaleaf Holdings, Dermapharm Holding, Almirall, HUTCHMED (China), and Fagron NV. Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy s... More
Stemtech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Stemtech's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Stemtech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 68.57 | |||
| Value At Risk | (26.47) | |||
| Potential Upside | 25.0 |
Stemtech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stemtech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Stemtech's standard deviation. In reality, there are many statistical measures that can use Stemtech historical prices to predict the future Stemtech's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (2.42) | |||
| Total Risk Alpha | (3.26) | |||
| Treynor Ratio | (0.68) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Stemtech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Stemtech February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.67) | |||
| Mean Deviation | 10.01 | |||
| Coefficient Of Variation | (631.12) | |||
| Standard Deviation | 13.97 | |||
| Variance | 195.25 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (2.42) | |||
| Total Risk Alpha | (3.26) | |||
| Treynor Ratio | (0.68) | |||
| Maximum Drawdown | 68.57 | |||
| Value At Risk | (26.47) | |||
| Potential Upside | 25.0 | |||
| Skewness | 0.4202 | |||
| Kurtosis | 1.1 |
Stemtech Backtested Returns
Stemtech owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.14, which indicates the firm had a -0.14 % return per unit of risk over the last 3 months. Stemtech exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Stemtech's Risk Adjusted Performance of (0.12), variance of 195.25, and Coefficient Of Variation of (631.12) to confirm the risk estimate we provide. The entity has a beta of 3.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Stemtech will likely underperform. At this point, Stemtech has a negative expected return of -2.01%. Please make sure to validate Stemtech's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Stemtech performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.69 |
Good predictability
Stemtech has good predictability. Overlapping area represents the amount of predictability between Stemtech time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Stemtech price movement. The serial correlation of 0.69 indicates that around 69.0% of current Stemtech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Stemtech reported net income of (7.08 Million). This is 102.07% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 101.24% higher than that of the company.
Stemtech Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stemtech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Stemtech could also be used in its relative valuation, which is a method of valuing Stemtech by comparing valuation metrics of similar companies.Stemtech is currently under evaluation in net income category among its peers.
Stemtech Fundamentals
| Return On Asset | -0.75 | |||
| Profit Margin | (1.85) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 8.79 M | |||
| Shares Outstanding | 48.63 M | |||
| Shares Owned By Insiders | 63.60 % | |||
| Price To Sales | 1.54 X | |||
| Revenue | 4.32 M | |||
| Gross Profit | 3.3 M | |||
| EBITDA | 1.58 M | |||
| Net Income | (7.08 M) | |||
| Cash And Equivalents | 399.73 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 219.47 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (1.91 M) | |||
| Earnings Per Share | 0.10 X | |||
| Market Capitalization | 6.52 M | |||
| Total Asset | 5.72 M | |||
| Z Score | 17.4 | |||
| Net Asset | 5.72 M |
About Stemtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stemtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stemtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stemtech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.